AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mage equations among races other than black
Number of subjects: 407
Study 24048361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologist-determined Fitzpatrick skin type (FST)
Number of subjects: 270
Study 24048361 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-determined Fitzpatrick skin type (FST)
Number of subjects: 270
Study 24048361 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant responses to burning
Number of subjects: 270
Study 24048361 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant responses to tanning
Number of subjects: 270
Study 24048361 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrophotometry measurements assessing FST
Number of subjects: 270
Study 24048627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg daily
Number of subjects: 0
Study 24048627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily
Number of subjects: 0
Study 24048627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (50.4 Gy in 28 fractions)
Number of subjects: 0
Study 24048627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib and irradiation
Number of subjects: 0
Study 24048673 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 co-infusion during hyperglycaemic clamps
Number of subjects: 11
Study 24048673 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP co-infusion during hyperglycaemic clamps
Number of subjects: 11
Study 24048673 — intervention group
Group type: COMPARATOR
Intervention: Saline co-infusion during hyperglycaemic clamps
Number of subjects: 11
Study 24048673 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative OGTT
Number of subjects: 11
Study 24049022 — intervention group
Group type: EXPERIMENTAL
Intervention: hHGF measurement on admission
Number of subjects: 73
Study 24049022 — intervention group
Group type: EXPERIMENTAL
Intervention: hHGF measurement 24 hours later
Number of subjects: 73
Study 24049022 — intervention group
Group type: EXPERIMENTAL
Intervention: hHGF increase
Number of subjects: 73
Study 24049022 — intervention group
Group type: COMPARATOR
Intervention: Normal hHGF concentration
Number of subjects: 73
Study 24049718 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II epiretinal prosthesis
Number of subjects: 0
Study 24049718 — intervention group
Group type: EXPERIMENTAL
Intervention: Full field stimulus light threshold measured using the Espion D-FST test
Number of subjects: 0
Study 24049718 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular contact of the array
Number of subjects: 0
Study 24050953 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily orally until unacceptable toxicity or disease progression
Number of subjects: 40
Study 24050955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-diagnostic β-blocker use
Number of subjects: 4794
Study 24050955 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4794
Study 24050955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no β-blocker use)
Number of subjects: 4794
Study 24051172 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus a taxane (docetaxel or paclitaxel)
Number of subjects: 41
Study 24051483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human breast milk (fHBM)
Number of subjects: 162
Study 24051483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 162
Study 24051483 — intervention group
Group type: COMPARATOR
Intervention: Human breast milk (HBM)
Number of subjects: 162
Study 24051744 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept
Number of subjects: 20
Study 24051744 — intervention group
Group type: COMPARATOR
Intervention: SPECT/CT
Number of subjects: 20
Study 24052462 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly continuous erythropoietin receptor activator (CERA)
Number of subjects: 348
Study 24053191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel, 120 mg every 28 days over ≤92 weeks
Number of subjects: 30
Study 24053191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel
Number of subjects: 30
Study 24053517 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP-LGI diet
Number of subjects: 10
Study 24053517 — intervention group
Group type: COMPARATOR
Intervention: NDP-LGI diet
Number of subjects: 10
Study 24053517 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 10
Study 24053656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily)
Number of subjects: 8282
Study 24053656 — intervention group
Group type: COMPARATOR
Intervention: Standard-therapy (enoxaparin 1.0 mg/kg twice-daily and warfarin or acenocoumarol)
Number of subjects: 8282
Study 24053656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8282
Study 24053656 — intervention group
Group type: COMPARATOR
Intervention: Standard-therapy
Number of subjects: 8282
Study 24055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with various treatments for T2DM
Number of subjects: 751
Study 24055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 751
Study 24055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measures using EQ-5D and ADDQoL
Number of subjects: 751
Study 24055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of hypoglycemia measured by HFS-II
Number of subjects: 751
Study 24055443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-coated sirolimus-eluting stent
Number of subjects: 0
Study 24055823 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic anti-CD19-CAR T cells
Number of subjects: 10
Study 24056237 — intervention group
Group type: EXPERIMENTAL
Intervention: High functioning ASD group
Number of subjects: 37
Study 24056237 — intervention group
Group type: COMPARATOR
Intervention: Neurotypical (NT) group
Number of subjects: 37
Study 24056477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced hand hygiene promotion
Number of subjects: 0
Study 24056477 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal MRSA screening with contact precautions and decolonisation (intranasal mupirocin and chlorhexidine bathing)
Number of subjects: 0
Study 24056477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enhanced hand hygiene and MRSA screening with contact precautions and decolonisation
Number of subjects: 0
Study 24056477 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA screening, contact precautions and decolonisation in clean surgery wards
Number of subjects: 0
Study 24057266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based follow-up visits
Number of subjects: 209
Study 24057266 — intervention group
Group type: COMPARATOR
Intervention: Remote monitoring strategy
Number of subjects: 209
Study 24057647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 16
Study 24058078 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²)
Number of subjects: 120
Study 24058078 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²) + Bare metal stent (BMS)
Number of subjects: 120
Study 24059479 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solution (BS) group
Number of subjects: 40
Study 24059479 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced solution (UBS) group
Number of subjects: 40
Study 24059787 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 0
Study 24059787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24062394 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver radiotherapy (RT)
Number of subjects: 41
Study 24062399 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for cancer
Number of subjects: 364
Study 24062399 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline Geriatric Depression Scale (GDS15)
Number of subjects: 364
Study 24062399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Instrumental Activities of Daily Living (IADL) scores
Number of subjects: 364
Study 24062895 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP testing
Number of subjects: 470
Study 24062895 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels below median (5000 pg/ml)
Number of subjects: 470
Study 24063518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional assessment including medical evaluation, neuropsychological test battery, anthropometric measurements, social and lifestyle interview, blood analyses, and storage of blood samples.
Number of subjects: 1644
Study 24063518 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal survey to be conducted two and four years after initial data collection.
Number of subjects: 1644
Study 24063569 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (self-reported inhaling ≥ 50 puffs per week since ≥ 6 months)
Number of subjects: 1500
Study 24063569 — intervention group
Group type: COMPARATOR
Intervention: Traditional cigarettes (≥ 1 per day since ≥ 6 months)
Number of subjects: 1500
Study 24063569 — intervention group
Group type: COMPARATOR
Intervention: Mixed users (both electronic and traditional cigarettes, ≥ 1 per day since ≥ 6 months)
Number of subjects: 1500
Study 24063569 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes
Number of subjects: 1500
Study 24063698 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle
Number of subjects: 19
Study 24063735 — intervention group
Group type: EXPERIMENTAL
Intervention: TG1042 (adenovirus vector expressing human interferon-gamma)
Number of subjects: 0
Study 24063848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 846
Study 24063848 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 846
Study 24064228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling initiated with surface cooling pads, followed by 1000-2000 mL of cold saline at hospital arrival and endovascular cooling in the catheterisation laboratory.
Number of subjects: 19
Study 24064318 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT) to a prescribed dose of 38.5 Gy in 10 fractions.
Number of subjects: 48
Study 24064318 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT).
Number of subjects: 48
Study 24065066 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary vitamin E intake
Number of subjects: 205
Study 24065066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dietary vitamin E intake
Number of subjects: 205
Study 24065152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study 24065152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (weight gain >4%)
Number of subjects: 0
Study 24065152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (weight gain no or little)
Number of subjects: 0
Study 24065445 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser-assisted retrieval
Number of subjects: 100
Study 24066670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 100 mg/kg after 2 Gy radiation
Number of subjects: 2
Study 24066670 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) at 5 mg/kg after 2 Gy radiation
Number of subjects: 2
Study 24066670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 100 mg/kg after 0.5 Gy radiation
Number of subjects: 2
Study 24066670 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) at 5 mg/kg after 0.5 Gy radiation
Number of subjects: 2
Study 24067666 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model for the management of SAM (IM-SAM)
Number of subjects: 2740
Study 24068445 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Doppler AVD optimization
Number of subjects: 50
Study 24068445 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded selection of optimum AVD
Number of subjects: 50
Study 24068445 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded selection of optimum AVD
Number of subjects: 50
Study 24068762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing intervention (10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily)
Number of subjects: 100
Study 24068762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing intervention
Number of subjects: 100
Study 24069180 — intervention group
Group type: EXPERIMENTAL
Intervention: WINROP (postnatal weight-gain algorithm)
Number of subjects: 707
Study 24069533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab treatment
Number of subjects: 144
Study 24070065 — intervention group
Group type: EXPERIMENTAL
Intervention: aPC infusion (24 mcg/kg/h for 96 hours)
Number of subjects: 22
Study 24070065 — intervention group
Group type: COMPARATOR
Intervention: no-aPC group
Number of subjects: 22
Study 24070658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician gestalt estimate for acute coronary syndrome
Number of subjects: 840
Study 24070658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician gestalt estimate for pulmonary embolism
Number of subjects: 840
Study 24070658 — intervention group
Group type: COMPARATOR
Intervention: Attribute matching for acute coronary syndrome
Number of subjects: 840
Study 24070658 — intervention group
Group type: COMPARATOR
Intervention: Attribute matching for pulmonary embolism
Number of subjects: 840
Study 24070658 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for clinician gestalt (acute coronary syndrome)
Number of subjects: 840
Study 24070658 — intervention group
Group type: COMPARATOR
Intervention: Receiver operating characteristic curve for attribute matching (acute coronary syndrome)
Number of subjects: 840
Study 24070658 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for clinician gestalt (pulmonary embolism)
Number of subjects: 840
Study 24070658 — intervention group
Group type: COMPARATOR
Intervention: Receiver operating characteristic curve for attribute matching (pulmonary embolism)
Number of subjects: 840
Study 24070982 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG performed on patients with AMS
Number of subjects: 259
Study 24070998 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging of embryos cultured for 6 days in a time-lapse incubator (EmbryoScope(™)), with automated image recording every 20 min.
Number of subjects: 20
Study 24070998 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging of embryos cultured for 6 days in a time-lapse incubator (EmbryoScope(™)).
Number of subjects: 20
Study 24073008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic treatment
Number of subjects: 32
Study 24073008 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard care
Number of subjects: 32
Study 24074142 — intervention group
Group type: EXPERIMENTAL
Intervention: SootherMask® designed from 3D anthropometric data
Number of subjects: 271
Study 24074142 — intervention group
Group type: EXPERIMENTAL
Intervention: Average masks from small, medium, and large clusters
Number of subjects: 271
Study 24075057 — intervention group
Group type: EXPERIMENTAL
Intervention: Expeditioners
Number of subjects: 25
Study 24075057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sherpas
Number of subjects: 25
Study 24075467 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure below the limits of cerebral autoregulation during cardiopulmonary bypass
Number of subjects: 450
Study 24075467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation monitoring
Number of subjects: 450
Study 24075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.2 mg/m(2) and idarubicin 8 mg/m(2)
Number of subjects: 20
Study 24075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 0.8 mg/m(2) and idarubicin 10 mg/m(2)
Number of subjects: 20
Study 24075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m(2) and idarubicin 10 mg/m(2)
Number of subjects: 20
Study 24075534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and idarubicin combination
Number of subjects: 20
Study 24075648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 484
Study 24075648 — intervention group
Group type: COMPARATOR
Intervention: No lifestyle intervention
Number of subjects: 484
Study 24075891 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE)
Number of subjects: 80
Study 24075891 — intervention group
Group type: COMPARATOR
Intervention: Small-bowel follow-through (SBFT)
Number of subjects: 80
Study 24075891 — intervention group
Group type: COMPARATOR
Intervention: Ileocolonoscopy
Number of subjects: 80
Study 24076529 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoChord DS1000 system (NeoChord, Inc.)
Number of subjects: 30
Study 24076532 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index (LAVi) ≥32 ml/m²
Number of subjects: 305
Study 24076532 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVi ≥32 ml/m²
Number of subjects: 305
Study 24076532 — intervention group
Group type: COMPARATOR
Intervention: LAVi <32 ml/m²
Number of subjects: 305
Study 24076699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid gel (mean of 163 ml per buttock)
Number of subjects: 8
Study 24076699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid gel
Number of subjects: 8
Study 24077565 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste-sensitive region of the caudal insula responding to food images
Number of subjects: 0
Study 24077565 — intervention group
Group type: COMPARATOR
Intervention: Rostral insula
Number of subjects: 0
Study 24077845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired ASXL1 mutations in patients with GATA2 deficiency
Number of subjects: 48
Study 24077845 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA2 deficiency patients with acquired ASXL1 mutation
Number of subjects: 48
Study 24077845 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 48
Study 24077846 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus sequential chemotherapy followed by autologous stem cell transplantation
Number of subjects: 58
Study 24077846 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic stem cell transplantation
Number of subjects: 58
Study 24077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (200 mg/day) with trastuzumab (4 mg/kg IV loading dose, then 2 mg/kg IV weekly) and paclitaxel (80 mg/m2 IV days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 21
Study 24077916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (120 up to 240 mg/day) with trastuzumab and paclitaxel
Number of subjects: 21
Study 24078868 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized texting for adherence building (iTAB)
Number of subjects: 29
Study 24078868 — intervention group
Group type: COMPARATOR
Intervention: Active comparison condition
Number of subjects: 29
Study 24078876 — intervention group
Group type: EXPERIMENTAL
Intervention: HEM-AVERT Perianal Stabilizer
Number of subjects: 98
Study 24078876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 98
Study 24079262 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination to guide fluid therapy
Number of subjects: 28
Study 24079306 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP2-based RDT
Number of subjects: 53
Study 24079306 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-based RDT
Number of subjects: 53
Study 24079306 — intervention group
Group type: COMPARATOR
Intervention: Giemsa-stained blood smear
Number of subjects: 53
Study 24079306 — intervention group
Group type: COMPARATOR
Intervention: Acridine orange-stained blood smear
Number of subjects: 53
Study 24079306 — intervention group
Group type: COMPARATOR
Intervention: Real-time PCR
Number of subjects: 53
Study 24079306 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recurrent infections
Number of subjects: 53
Study 24079475 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) measurement
Number of subjects: 131
Study 24079475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound dating scans
Number of subjects: 131
Study 24079475 — intervention group
Group type: COMPARATOR
Intervention: Last menstrual period (LMP) estimates
Number of subjects: 131
Study 24079716 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix (RIX4414) - two doses (0, 2-month schedule)
Number of subjects: 15
Study 24079716 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 24079992 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME intervention (Health Centre Management, Fever Case Management, Patient-Centered Services, support for supplies of malaria diagnostics and antimalarial drugs)
Number of subjects: 0
Study 24079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker training, health centre management tools, supply of artemether-lumefantrine (AL) and rapid diagnostic tests (RDTs) for malaria
Number of subjects: 0
Study 24079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing hypotheses and interpreting realities of the intervention
Number of subjects: 0
Study 24079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual record of factors affecting implementation
Number of subjects: 0
Study 24079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Broader impacts of the intervention and trial activities
Number of subjects: 0
Study 24080250 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 42
Study 24080250 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast withdrawal
Number of subjects: 42
Study 24080704 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical diabetic macular edema (DME)
Number of subjects: 348